April 2021

Abstract 4: REGN-COV2, an Antibody Cocktail, in Outpatients with COVID-19

EMA 2021 April26 Chapters

  1. Introduction4:34
  2. Ultra Summary28:58
  3. Time To Talk A Little Nerdy: Logical Fallacies - Part II17:42
  4. Farewell1:52
Sign in or subscribe to listen

No me gusta!

The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.

Ian L. -

Likely to be Marginal ? Not so according to some claims . -March 10 2021 -Vir Biotechnology and GSK claim a monoclonal VIR 7831 which targets a "highly conserved epitope" on SARS-CoV-2 Shared with SARS-CoV-1 given IV to patients at high risk of hospital admission -291 in treatment arm 292 placebo led to an 85 % reduction in hospitalisation or death . -Called the COMET-ICE Trial . -Independent Data Monitoring Committee(IDMC ) said to have stopped trial because of profound efficacy . -Hopefully a second chance for those not vaccinated because of hesitancy or lack of reach .

Mike M. -

I will stick to my guns on this one. These things are totally unproven. a new monoclonal Ab LY-CoV555 was just reported in NEJM to be useless in hospitalized patients. Other reports have shown monoclonal antibodies may be harmful for hospitalized patients. The cocktail product claims in a press release to reduce admissions from 3% to 1%. The information is not peer-reviewed but this would seem to be a marginal effect.

To join the conversation, you need to subscribe.

Sign up today for full access to all episodes and to join the conversation.

To earn CME for this chapter, you need to subscribe.

Sign up today for full access to all episodes and earn CME.

6 AMA PRA Category 1 Credits™ certified by PIM

  1. Quiz Not Required
  2. Complete Evaluation
  3. Print Certificate